Chinese firm is granted licensing rights to BioLineRx's hep C drug

06/11/2013 | Pharmaceutical Business Review Online · Globes (Israel)

Jiangsu Chia-tai Tianqing Pharmaceutical secured exclusive rights to develop, produce and bring to market BioLineRx's BL-8030, an oral hepatitis C drug candidate, in China and Hong Kong. BioLineRx will keep the drug's development and commercialization rights in other parts of the world. The deal entitles BioLineRx to as much as $30 million in upfront and milestone fees plus sales royalties.

View Full Article in:

Pharmaceutical Business Review Online · Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA